Scott Clarke

Outlook Typekit Mobile Friendly WordPress.org Nginx

biotechnology research gdf-15 visugromab monoclonal antibody immunotherapy cancer therapy anti-tumor efficacy checkpoint inhibitors tumor evasion cancer cachexia phase 2b clinical trials t cell activation solid tumors biopharmaceutical clinical development immune resistance tumor microenvironment resistance mechanisms clinical data medical oncology biotech potential treatment options durable responses t cell infiltration anti-pd-1 treatment gdf-15 neutralization cancer patient needs cachexia treatment lifting immunosuppression quality of life cancer indications investigational new drugs therapeutic approaches preclinical studies patient tolerability tumor-derived factors research & development clinical proof of concept gdf-15 blockade immune cell proliferation biomarker analysis patient outcomes treatment regimens cancer immunology safety profile biotherapeutics therapy combination solid tumor indications